Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 12:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 168 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eosinophilic Esophagitis (EoE) Clear all
Completed Phase 3 Interventional Results available

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

NCT04991935
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
CC-93538
Drug
Lead sponsor
Celgene
Industry
Eligibility
12 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

NCT00635089
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
reslizumab
Drug
Lead sponsor
Ception Therapeutics
Industry
Eligibility
5 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Intravenous Mepolizumab In Children With Eosinophilic Esophagitis

NCT00358449
View directory record Official record
Conditions
Oesophagitis, Eosinophilic
Interventions
mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Tampa, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 9, 2026, 12:03 PM EDT
Not listed Phase 4 Interventional

Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)

NCT04149470
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Omeprazole 20mg BID
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 22 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 9, 2026, 12:03 PM EDT
Completed No phase listed Observational

Eosinophilic Esophagitis Databank

NCT01323803
View directory record Official record
Conditions
Esophagitis, Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 65 Years
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 9, 2026, 12:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Data Bank for Eosinophilic Disorders

NCT00267475
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastritis, Enteritis, Eosinophilic Colitis, Eosinophilic Gastroenteritis
Interventions
Not listed
Lead sponsor
Marc Rothenberg
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 9, 2026, 12:03 PM EDT
Completed No phase listed Observational

Risk Factors and Biomarkers for Diagnosis and Treatment of EoE

NCT01988285
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Specimen Collection, Questionnaires
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 9, 2026, 12:03 PM EDT
Active, not recruiting Phase 2 Interventional

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

NCT06851559
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
41
States / cities
Little Rock, Arkansas • Chula Vista, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 9, 2026, 12:03 PM EDT
Active, not recruiting Phase 4 Interventional

Dupilumab for Eosinophilic Esophagitis With Severe Strictures

NCT06352073
View directory record Official record
Conditions
Eosinophilic Esophagitis, EoE
Interventions
Dupilumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis

NCT00762073
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
budesonide, placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
2 Years to 18 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 9, 2026, 12:03 PM EDT
Recruiting Not applicable Interventional

Impact of Body Positioning on EndoFLIP Measurements: A Comparative Study of Supine and Left Lateral Decubitus Positions

NCT07780981
View directory record Official record
Conditions
Dysphagia, Esophageal Stricture, Epidermolysis Bullosa (EB), Achalasia, Esophageal Motility Disorders, Eosinophilic Esophagitis (EoE)
Interventions
EndoFlip
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Years to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 9, 2026, 12:03 PM EDT
Terminated Phase 2 Interventional Results available

Antihistamines in Eosinophilic Esophagitis

NCT04248712
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Famotidine, Loratadine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 9, 2026, 12:03 PM EDT
Recruiting Phase 4 Interventional

Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)

NCT06665971
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

NCT04394351
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Dupilumab, Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year to 11 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 9, 2026, 12:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Utility of Mucosal Impedance Device in Chronic Esophageal Disorders:

NCT07227506
View directory record Official record
Conditions
Gerd, Eosinophilic Esophagitis
Interventions
MuVI Esophageal mucosal impedance testing
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

NCT03633617
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
62
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 1 Interventional

Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients

NCT01641913
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Absorbable sugars
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 9, 2026, 12:03 PM EDT
Recruiting No phase listed Observational

Indiana University Gastrointestinal Motility Diagnosis Registry

NCT04506593
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease (GERD), Gastroparesis, Functional Vomiting, Irritable Bowel Syndrome (IBS), Constipation, Chronic Intestinal Pseudo-obstruction, Fecal Incontinence, Small Intestinal Bacterial Overgrowth
Interventions
no intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 9, 2026, 12:03 PM EDT
Withdrawn Not applicable Interventional

Short Duration 6Fed Sponge For EoE Patients

NCT03354221
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Cytosponge, Diet, EEsAI Pro, Likert Scoring Scale
Device · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 9, 2026, 12:03 PM EDT
Terminated Phase 2 Interventional Results available

Bethanechol for Eosinophilic Esophagitis

NCT02058537
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Bethanechol
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 22, 2016 · Synced Oct 9, 2026, 12:03 PM EDT
Completed No phase listed Observational

Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?

NCT01865825
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Esophageal Barium Xray
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial of Montelukast in Eosinophilic Esophagitis

NCT00511316
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Montelukast/ Singulair, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 3 Interventional

A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders

NCT00266578
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Fluticasone Propionate
Drug
Lead sponsor
Marc Rothenberg
Other
Eligibility
3 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 9, 2026, 12:03 PM EDT
Recruiting Not applicable Interventional

Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis

NCT07234825
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Partial enteral nutrition (PEN) with dairy elimination, Dairy elimination alone
Other
Lead sponsor
Kate Farms Inc
Industry
Eligibility
1 Year to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 9, 2026, 12:03 PM EDT